期刊文献+

子宫内膜癌组织中抑癌基因PTEN突变分析 被引量:6

Tumor Suppressor Gene PTEN Mutations in Endometrial Neoplasm
下载PDF
导出
摘要 目的 了解子宫内膜癌组织中磷酸酶基因PTEN突变情况及其与临床病理特征的关系。方法 采用聚合酶链反应 单链构象多态性方法 (PCR SSCP)对 70例子宫内膜癌组织进行PTEN基因 9个外显子的突变检测。结果  70例子宫内膜癌组织中PTEN基因突变率为 38.5 7% ( 2 7/70 ) ,突变较多地分布在第 5、7、8号外显子上 ;子宫内膜样癌突变率 ( 4 4.8% )明显高于浆液性和粘液性腺癌 ( 8.3% ) ,P <0 .0 5 ,G 1级、G 2级、G 3级的突变率分别为 5 3.3%、45 .5 %、18.2 % (P <0 .0 5 ) ,Ⅰ期、Ⅱ期、Ⅲ~Ⅳ期的突变率分别为 5 2 .4%、2 8.6 %、14 .3% (P <0 .0 5 ) ,肌层浸润程度越深 ,突变率越低 (P <0 .0 5 )。结论 PTEN基因突变是子宫内膜癌发生的早期事件 ,并与预后良好的临床病理特点相关。 Objective To detect the PTEN gene mutation in endometrial cancer and to analyze the relationship between PTEN mutation and clinical-pathologic characteristics.Methods PTEN mutations in all nine exons were detected by single-strand conformational polymorphism(SSCP) and silver stain in 70 cases of endometrial neoplasm.Results Mutations were noted in 27 of 70(38.6%),and exon 5,7,8 were the most frequently mutated locations.Mutations were seen only in 8.3%(1 of 12) of serous(n=9)and mucinous(n=3) cancers compared with 44.8%(26 of 58) of endometrioid cancer(P<0.05).The percentage of mutation in stage I,stage Ⅱ and Ⅲ/Ⅳ was 52.4%,28.6%,14.3% respectively(P<0.05).The deeper the myometrial invasion was,the lower the mutation rate was(P<0.05).Mutation in Grade 1 and 2 was more common than that in Grade 3(P<0.05).Conclusion PTEN mutation is early event of endometrial cancer,and associated with favorable pathological clinical features.
出处 《实用癌症杂志》 2001年第6期587-590,共4页 The Practical Journal of Cancer
关键词 子宫内膜癌 聚合酶链反应-单链构象多态性分析法 抑癌基因 PTEN 基因突变 Endometrial cancer Gene Phosphatase Mutation PCR-SSCP analysis
  • 相关文献

参考文献11

  • 1Li J, Yen C,Liaw D,et al. PTEN: a putative protein tyrosine phosphatase gene mutated in human brain, breast,and prostate cancer[J ]. Science, 1997,275(3) :1943.
  • 2Maehama T,Dixion JE. The tumor suppressor,PTEN/MMAC1, dephosphorylates the lipid second messenger,phosphatidylinositol 3, 4, 5-trisphosphate [J ]. J Biol Chem, 1998,273(5): 13375.
  • 3Tamura M,Gu ],Matsumoto K,et al. Inhibition of cell migration,spreading, and focal adhesions by tumor suppressor PTEN[J]. Science, 1998,280(6): 1614.
  • 4Gu J,Tamura M, Yamada KM,et al. Tumor suppressor PTEN inhibits integrin-and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways[J]. J Cell Biol, 1998,143 (5): 1375.
  • 5Kong D, Suruki A, Zou TT, et al. PTEN is frequently mutated in primary endometrial carcinomas [J]. Nat Genet, 1997, 17(2): 143.
  • 6Risinger JI, Hayes K, Maxwell GL,et al. PTEN nutation in endometrial cancers is associated with favorable clinical and pathologic characteristics [J]. Clin Cancer Res, 1998,4 (12): 3005.
  • 7Imamura T, Arima T, Kato T,et al. Chromosomal deletions and K-ras gene mutations in human endometrial carcinomas[J]. Int J Cancer, 1992,51(9)51:47.
  • 8Risinger J, Dent GA, Ignar-towbridge D, et al. p53 gene mutations in human endometrial carcinoma[J]. Mol Carcinog, 1992,5(4) :250.
  • 9Steck PA, Perhouse MA,Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in mutiple advanced cancers[J]. Nat Genet, 1997,15(4): 356.
  • 10Tashiro H,Blazes MS,Wu R,et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies [J ]. Cancer Res,1997,57(9) :3935.

同被引文献39

  • 1徐少婷,郑艳,滕晓东,苏玲娣.p16^(INK4)、p21^(ras)及p185^(C-erbB-2)蛋白在子宫内膜癌的表达及临床病理意义[J].实用妇产科杂志,2005,21(4):220-222. 被引量:6
  • 2朱有法,朱景旭,许敬尧.大肠腺瘤不典型增生及癌变组织中p53基因的表达及意义[J].中华病理学杂志,1996,25(5):306-306. 被引量:6
  • 3常晓华,姜爱民,张超,梁桃,宋吉涛,郭晓华.大肠癌中Survivin、PTEN、p16的表达及其临床意义[J].中国临床医学,2007,14(1):31-32. 被引量:5
  • 4Sun H, Enomoto T, Fujita M, et al. Mutational analysis of thePTEN gene in endometrial carcinoma and hyperplasia [ J ]. Am J Clin Pathol,2001,115 :32-38.
  • 5Chu EC,Tarnawski AS. PTEN regulatory functions in tumor suppression and cell biology Med[ J]. Sci Monut,2004,10 (10) :235-241.
  • 6Minaguchi T,Yoshikawa H,Oda K,et al. PTEN mutation locatedonly outside exons 5,6 AND 7 is an independ-ent predictor of favorable survival in endometrial carcinomas [ J] Clin Cancer Res,2001,7: 2636 -2642.
  • 7Han SY,Kato H, KatoS,et al. Function evaluation of PTEN missense mutations using in viro phosphoinositide phosphatase assay[J]. Cancer Res,2006,60(12) :3147-3151.
  • 8Cerezo L,Cardenes H,Michael H. Molecular alterations in the pathogenesis of endometrial adenocarcinoma. Therapeutic imp lications [ J ]. Clin TrainsOncol,2006,8 (4) : 231-241.
  • 9Tamuram G J, MatsumotoK, AotaS, et al. lnhibltion of migration, spreading, and adhensions by tumer suppressor PTEN [ J ]. Science, 2004,280 (5369) : 1614-1617.
  • 10Tashiro H, Blazes M S, Wu R, et all Mutations in PTEN are frequent in endometrial carcinoma but rare in other gynecological malignancies [J]. Cancer Res,1997,57(18) :3935-3940.

引证文献6

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部